HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Senores Pharmaceuticals inks agreement to acquire ANDA for Topiramate HCl 25, 50, 100, 200 mg tablets
May-05-2025

Senores Pharmaceuticals (SPL), through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA (SPI), has signed agreement to acquire the USFDA-approved Abbreviated New Drug Application (ANDA) for Topiramate HCl 25, 50, 100 and 200 mg tablets (Topiramate) from Wockhardt.

Topiramate is indicated as a treatment of epilepsy and migraine. The market size of Topiramate Tablet in the USA was around $111.47 million (MAT December 2024) as per IQVIA. The acquisition will be funded through the Initial Public Offer (IPO) proceeds raised by SPL. This is in line with objects of the IPO stated in the Red Herring Prospectus.

Senores Pharmaceuticals is global research driven pharmaceutical company engaged in developing and manufacturing a wide range of generic pharmaceutical products in the B2B segment predominantly for the Regulated Markets across various therapeutic areas and dosage forms. 

  RELATED NEWS >>